Robotic Mechanical Thrombectomy (rMT)

• Robotic Mechanical Thrombectomy (rMT) is an automated procedure that removes blood clots in acute stroke through advanced robotics and integrated sensor feedback.
• It employs hierarchical multi-agent and inverse reinforcement learning methods to optimize navigation, safety, and multi-anatomy performance.
• rMT systems combine precise actuation and sim-to-real transfer strategies to address challenges in device integration, anatomical diversity, and regulatory compliance.

Robotic Mechanical Thrombectomy (rMT) is the technology-driven execution and automation of endovascular procedures designed to remove intravascular thrombi, most often in the context of acute ischemic stroke, using robotic platforms to manipulate catheters, guidewires, or novel intravascular devices. The integration of reinforcement learning (RL), inverse reinforcement learning (IRL), closed-loop sensing, and advanced actuation architectures has enabled significant advances in navigation, safety, and clinical performance for rMT.

1. Fundamental Approaches to Autonomy and Control

Recent progress in rMT is marked by the development of advanced autonomy frameworks based on hierarchical modular multi-agent RL (HM-MARL), soft actor-critic (SAC) RL, TD-MPC2 world models, and IRL-derived reward functions.

Hierarchical Modular Multi-Agent Reinforcement Learning (HM-MARL) decomposes the long-horizon navigation from femoral access to the internal carotid artery (ICA) into sequential sub-tasks (A₁…A₅), each controlled by a specialist SAC agent. A rule-based Task-Selection Module (TSM) determines which agent's action to execute based on real-time tip location within vascular segments. Each agent's state comprises three 2D tip-tracking points, the current target centerline point, and the previous action; control actions for both guidewire and catheter are two-dimensional (proximal-end rotation ω ∈ [–180°, 180°]/s and translation v ∈ [–40, +40] mm/s) (Robertshaw et al., 20 Feb 2026).

Reward shaping in these paradigms typically follows: $$R_t = -1.5\times 10^{-4} - 0.001\,\Delta {\text{pathlength}}_t + \begin{cases} 1, & \text{if}\ \lVert \text{tip}-\text{target}\rVert \leq r_{\text{vessel}} \ 0, & \text{else} \end{cases}$$ This incentivizes forward progress and penalizes dithering, with a sparse terminal bonus for reaching the goal.

World model-based RL (TD-MPC2) introduces learned latent representations $z_t$, capturing observed tip positions, target, and prior actions, and simulates future vascular states via a transition model. This allows the agent to "imagine" device dynamics and feedback for improved generalization over multi-task and multi-patient scenarios (Robertshaw et al., 29 Sep 2025).

Inverse RL (IRL) frameworks infer reward functions directly from expert demonstrations, enabling agents to replicate complex, expert-level navigation strategies. Shaped reward functions, produced by augmenting IRL-derived rewards with additional geometric or progress-based terms, yield superior generalization and procedure times compared to dense or IRL-only rewards (Robertshaw et al., 2024).

2. In Silico and In Vitro Performance: Success Rates and Generalizability

Empirical validation of RL-driven rMT strategies is typically performed on stEVE/SOFA-based vasculature simulations and 3D-printed phantom setups.

• HM-MARL achieves 92–100% success rates on right ICA navigation in single (in silico) anatomies and 56–80% in ten-anatomy, multi-patient generalization tasks (in silico). In vitro phantoms, using overhead 4K cameras and stepper-motor robots actuating standard guidewires and catheters, demonstrate 100% right common carotid artery (CCA) cannulation and 80% right ICA navigation, but no left ICA success with a straight catheter (Robertshaw et al., 20 Feb 2026).
• Single-agent SAC policies fail to complete long-horizon navigation in multi-anatomy in silico settings (0% full-path success; significant drop relative to modular agents).
• Force-aware, dual-device RL algorithms demonstrate 96% success for autonomous navigation from ICA to middle cerebral artery (MCA) in 12 distinct patient-specific cerebral models, with mean forces (0.24 N) well below the vessel rupture threshold (1.5 N) (Robertshaw et al., 31 Mar 2025).
• World model-based TD-MPC2 agents, trained on ten anatomies, achieve 65% success and 73% path ratio (distance traveled/optimal path), versus 37% success and 47% path ratio for SAC, confirming improved multi-task transfer at the cost of increased procedure time (Robertshaw et al., 29 Sep 2025).
• IRL-based and shaped-reward agents: Reward shaping yields 100% dual-device navigation success and 22.6 s average procedure time; pure IRL reward models underperform on the chosen centerline-based metrics (48% success, 59.2 s), often due to bias in learned rewards favoring non-target vessel branches (Robertshaw et al., 2024).

3. Actuation Architectures and Sensor Integration

Robotic actuation strategies in rMT encompass both traditional mechanical and advanced wireless approaches.

• Stepper motor-driven robots deliver controlled translation and rotation to standard endovascular devices with sub-millimeter tip accuracy. Modular carriage designs allow for concentric or parallel device deployment and are compatible with clinical guidewires (e.g., Terumo 0.035″) and catheters (e.g., Navien, Neuron MAX) (Robertshaw et al., 20 Feb 2026).
• Magnetic milli-spinners provide a wireless alternative, leveraging rotating magnetic fields (generated via three-axis Helmholtz coils up to 20 mT) to actuate untethered, helical-finned devices for high-speed navigation (up to 55 cm/s, ∼175 body lengths per second) and high-efficiency clot debulking (Lu et al., 4 Jan 2026). Geometric optimization (fin number Nₓ=3, helix angle α=60°, slit ratio w*=0.75, r/L_fin=1.25) maximizes upstream propulsion and pressure differentials for clot suction.
• Surgical dissecting robots utilize a concentric push/pull robot (CPPR) architecture with dual-bending segments and internal lumen for suction, irrigation, and an endoscopic camera, supporting distal navigation (95 cm³ workspace, 2 mm accuracy) and effective clot stripping in ex vivo pulmonary models (Zhu et al., 3 Feb 2026).

Sensor feedback integration remains critical for safety and outcome optimization:

• Vacuum-excitation sensing: An extracorporeal pressure transducer connected to the aspiration catheter detects tip–thrombus contact using sinusoidal syringe actuation (4 Hz, 0.4 mL), with a gauge pressure sensor and SVM classifier (RBF kernel) achieving 99.67% benchtop accuracy and a 2.86× improvement in clinical contact detection odds (p=0.03) (Lawson et al., 2024).
• Force/torque feedback: Robot joint currents or simulated tip force are incorporated into the RL reward to penalize excessive vessel-wall interaction and minimize vessel injury risk (Robertshaw et al., 31 Mar 2025).

4. Simulation-to-Real Transfer: Challenges and Strategies

Key simulation-to-real (sim2real) transition barriers include:

• Friction, compliance, and dynamics mismatches: Simulated parameters (e.g., friction coefficients, bending stiffness) are environment-tuned and may not match 3D-printed or clinical tissue, impacting in vitro and in vivo reproducibility (Robertshaw et al., 20 Feb 2026).
• Control rate inflation: In vitro robots exhibit step delays (e.g., 0.5 s per move to prevent motor overheating), leading to ∼10× longer procedure times than simulation.
• Imaging domain gap: Simulations provide perfect state; in vitro/ex vivo setups rely on vision-based tip tracking, susceptible to noise and occlusion.

Proposed mitigation measures:

• Enhanced domain randomization during sim training (friction, compliance, anatomy scale, imaging noise).
• Learned world models (TD-MPC2) enabling the agent to adapt to unseen environments by "imagining" vascular dynamics (Robertshaw et al., 29 Sep 2025).
• Force/torque inclusion in RL states and rewards.
• Transition to end-to-end image-based RL (raw fluoroscopy as agent input) to reduce dependency on engineered state vectors (Robertshaw et al., 20 Feb 2026).
• Learnable TSM modules for sub-policy switching under uncertainty.

5. Clinical Integration, Safety, and Regulatory Considerations

For clinical translation, rMT platforms must meet stringent performance and safety criteria.

• Safety boundaries: Hard limits are enforced (force ≤ 1.5 N, rotation ±180°/s, translation ±40 mm/s). RL and controller inference cycles are required to execute within tight real-time deadlines (e.g., 50 ms/cycle).
• Shared-autonomy (human-in-loop) models are singled out as the immediate path to CE/FDA approval under MDR 2017/745 (EU) or FDA SaMD regulation, due to accountability and unpredictability of full autonomy.
• Biocompatibility and device integration: 3D printed materials, adhesives, and actuation artifacts (eddy current, viscous heating) must not exceed endothelial damage thresholds (~100 Pa shear stress, <2°C temperature rise) (Lu et al., 4 Jan 2026).
• Sterilization and durability: Surgical dissectors and milli-spinners must adhere to ISO 10993 (materials), ICNIRP (magnetic field exposure), and withstand repeated cycles without mechanical degradation (Zhu et al., 3 Feb 2026).

6. Limitations, Open Challenges, and Future Research Directions

Current rMT systems exhibit several limitations:

• Anatomical diversity: Most validation involves one or a few anatomical models (phantoms or CT-derived vasculatures). Expansion to more patient-specific geometries, including variations of the Circle of Willis, is needed (Robertshaw et al., 20 Feb 2026).
• Device diversity: Straight catheters underperform on left-sided or highly tortuous paths; work is ongoing to adapt these algorithms to shaped and microcatheters, as well as micro-guidewires (Robertshaw et al., 31 Mar 2025).
• Distal navigation and clot retrieval: Full-pathway automation (A₄/A₅) for clot engagement and extraction remains an open problem.
• Sensory limitations: Absence of high-resolution force sensing and visual feedback constrains safe manipulation in distal/scarce vessel regions (Zhu et al., 3 Feb 2026).
• Phantom vs. in vivo gap: Elastic, compliant, pulsatile vasculature, blood viscosity, and clot morphologies are not yet fully modeled or validated (Lawson et al., 2024).

Planned future avenues include:

• In vivo (animal/cadaver) and ex vivo validation for real compliance and flow.
• Closed-loop force and imaging augmentation (e.g., MRI compatibility, ultrasound tracking, fluorescence monitoring).
• End-to-end computer vision pipelines for RL using raw imaging data.
• Data-driven self-calibration: Tele-operated data collection for patient- and operator-specific IRL reward estimation, expediting clinical system deployment (Robertshaw et al., 2024).
• Streaming sensory inference and miniaturization of sensor/actuator packages for improved operator feedback in live procedures.

---

Summary Table: Key RL-Based Robotic MT Results

System/Study	Navigation Success	Real Model Proof	Safety Feedback	Notable Limitation
HM-MARL (Robertshaw et al., 20 Feb 2026)	100% right ICA (in silico, in vitro); 80% right ICA (in vitro)	Yes (phantom)	No (motor currents planned)	No left ICA with straight catheters
TD-MPC2 (Robertshaw et al., 29 Sep 2025)	65% (10 anatomies, multi-task)	No	No	High PT, imaging domain gap
Safe Dual-Device RL (Robertshaw et al., 31 Mar 2025)	96% to MCA (sim)	No	Force (0.24 N avg)	2D simulation only
IRL and Reward Shaping (Robertshaw et al., 2024)	100% (dual-device, shaped); 48% (IRL-only)	No	No	Reward misspecification, state realism

---

Robotic mechanical thrombectomy has advanced from proof-of-concept simulation to in vitro validation of multi-agent, safety-aware, and data-driven navigation policies, with optimized actuation and sensing systems. Primary barriers to clinical adoption remain sim2real translation, regulatory integration, sensory feedback completeness, and anatomical generalizability. Ongoing research focuses on world model RL, imaging-based perception, improved phantoms and in vivo testing, and hybrid autonomy frameworks compatible with existing clinical workflows.